title: Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
abstract: Dalbavancin is a novel parenteral lipoglycopeptide antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults. Dalbavancin is highly active against common Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Dalbavancin has a prolonged half-life that allows for once weekly dosing. Phase III trials have demonstrated non-inferiority compared with vancomycin/linezolid in the treatment of ABSSSIs, including those sustained by MRSA.
authors.affiliation: Department of Medicine and Surgery, University of Salerno, Italy.
authors.forename: Silvano
authors.initials: S
authors.lastname: Esposito
authors.affiliation: Department of Medicine and Surgery, University of Salerno, Italy.
authors.forename: Silvana
authors.initials: S
authors.lastname: Noviello
authors.affiliation: Department of Medicine and Surgery, University of Salerno, Italy.
authors.forename: Sebastiano
authors.initials: S
authors.lastname: Leone
mesh_terms: D061605:Administration, Intravenous; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D016032:Randomized Controlled Trials as Topic; D017192:Skin Diseases, Bacterial / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy; D017334:Teicoplanin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D017334:Teicoplanin; C469289:dalbavancin